In monotherapy or combination therapy, the anti-Tim3 antibody RMT3–23 exhibits significant antitumor efficacy in several types of cancer, such as MCA-induced sarcoma [64], colon adenocarcinoma [64], lung cancer [60], ID8 ovarian cancer [65], melanoma [63], and murine glioma [66]. Here, HAVCR2 is linked to cancer.